Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease

Journal of Lipid Research

Volumn 54, Issue 11, 2013, Pages 3189-3197

  Qi, Yue ^a,b   Liu, Jing ^a,b   Ma, Changsheng ^a   Wang, Wei ^a,b   Liu, Xiaohui ^a   Wang, Miao ^a,b   Lv, Qiang ^a   Sun, Jiayi ^a,b   Liu, Jun ^a,b   Li, Yan ^a,b   Zhao, Dong ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF HEART   (China)

Author keywords

Cholesterol absorption marker; Cholesterol synthesis marker; Low density lipoprotein cholesterol

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CAMPESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL ABSORPTION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

CHOLESTEROL ABSORPTION MARKER; CHOLESTEROL SYNTHESIS MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABSORPTION; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; RISK;

EID: 84885984478     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P040360     Document Type: Article

References (42)

1. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239. (Pubitemid 38924592)
2. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
3. Adams, S. P., M. Tsang, and J. M. Wright. 2012. Lipid lowering effi cacy of atorvastatin. Cochrane Database Syst. Rev. 12: CD008226.
4. Andrews, T. C., C. M. Ballantyne, J. A. Hsia, and J. H. Kramer. 2001. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111: 185-191. (Pubitemid 32786945)
5. Thom, T., N. Haase, W. Rosamond, V. J. Howard, J. Rumsfeld, T. Manolio, Z. J. Zheng, K. Flegal, C. O'Donnell, S. Kittner, et al. 2006. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 113: e85-e151.
6. Ebrahim, S., and G. D. Smith. 2000. Statins and risk of coronary heart disease. JAMA. 283: 2935-2936.
7. Davis, H. R., Jr., L. J. Zhu, L. M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S. P. Iyer, M. H. Lam, E. G. Lund, et al. 2004. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279: 33586-33592. (Pubitemid 39063007)
8. Hoenig, M. R., B. E. Rolfe, and J. H. Campbell. 2006. Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis. 184: 247-254. (Pubitemid 43049707)
9. Descamps, O. S., J. De Sutter, M. Guillaume, and L. Missault. 2011. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis. 217: 308-321.
10. Lupattelli, G., S. De Vuono, and E. Mannarino. 2011. Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 21: 620-627.
11. Mackay, D. S., and P. J. Jones. 2012. Plasma noncholesterol sterols: current uses, potential and need for standardization. Curr. Opin. Lipidol. 23: 241-247.
12. Kastelein, J. J., F. Akdim, E. S. Stroes, A. H. Zwinderman, M. L. Bots, A. F. Stalenhoef, F. L. Visseren, E. J. Sijbrands, M. D. Trip, E. A. Stein, et al. 2008. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358: 1431-1443. (Pubitemid 351482735)
13. Catapano, A., W. E. Brady, T. R. King, and J. Palmisano. 2005. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr. Med. Res. Opin. 21: 1123-1130. (Pubitemid 41032704)
14. Miettinen, T. A., T. E. Strandberg, and H. Gylling. 2000. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20: 1340-1346. (Pubitemid 30262937)
15. Miettinen, T. A., and H. Gylling. 2002. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis. 164: 147-152. (Pubitemid 34773441)
16. Miettinen, T. A., H. Gylling, N. Lindbohm, T. E. Miettinen, R. A. Rajaratnam, and H. Relas. 2003. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J. Lab. Clin. Med. 141: 131-137. (Pubitemid 36216566)
17. Wu, W. F., Q. H. Wang, T. Zhang, S. H. Mi, Y. Liu, and L. Y. Wang. 2013. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease. Clin. Biochem. 46: 993-998.
18. van Himbergen, T. M., N. R. Matthan, N. A. Resteghini, S. Otokozawa, M. Ai, E. A. Stein, P. H. Jones, and E. J. Schaefer. 2009. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res. 50: 730-739.
19. Jakulj, L., M. N. Vissers, A. K. Groen, B. A. Hutten, D. Lutjohann, E. P. Veltri, and J. J. Kastelein. 2010. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J. Lipid Res. 51: 755-762.
20. Lakoski, S. G., F. Xu, G. L. Vega, S. M. Grundy, M. Chandalia, C. Lam, R. S. Lowe, M. E. Stepanavage, T. A. Musliner, J. C. Cohen, et al. 2010. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95: 800-809.
21. Matthan, N. R., N. Resteghini, M. Robertson, I. Ford, J. Shepherd, C. Packard, B. M. Buckley, J. W. Jukema, A. H. Lichtenstein, and E. J. Schaefer. 2010. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J. Lipid Res. 51: 202-209.
22. Thongtang, N., J. Lin, E. J. Schaefer, R. S. Lowe, J. E. Tomassini, A. K. Shah, and A. M. Tershakovec. 2012. Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis. 225: 388-396.
23. Li, H. J., J. Liu, W. Wang, L. P. Qin, Y. Li, M. Wang, J. Y. Sun, Y. Qi, and D. Zhao. 2010. Real world use of statins for secondary prevention in patients with high risk coronary heart disease in China (in Chinese). Zhonghua. Xin Xue Guan Bing Za Zhi. 38: 1033-1037.
24. Barnett, A. G., J. C. van der Pols, and A. J. Dobson. 2005. Regression to the mean: what it is and how to deal with it. Int. J. Epidemiol. 34: 215-220. (Pubitemid 40347398)
25. Laird, N. 1983. Further comparative analyses of pretest-posttest research designs. Am. Stat. 37: 329-330.
26. Simonen, P. P., H. K. Gylling, and T. A. Miettinen. 2002. Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care. 25: 1511-1515. (Pubitemid 41071103)
27. Miettinen, T. A., and H. Gylling. 2003. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33: 976-982. (Pubitemid 37421596)
28. Escurriol, V., M. Cofan, C. Moreno-Iribas, N. Larranaga, C. Martinez, C. Navarro, L. Rodriguez, C. A. Gonzalez, D. Corella, and E. Ros. 2010. Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. J. Lipid Res. 51: 618-624.
29. Naumann, E., J. Plat, and R. P. Mensink. 2003. Changes in serum concentrations of noncholesterol sterols and lipoproteins in healthy subjects do not depend on the ratio of plant sterols to stanols in the diet. J. Nutr. 133: 2741-2747. (Pubitemid 37099754)
30. Zhai, F., H. Wang, S. Du, Y. He, Z. Wang, K. Ge, and B. M. Popkin. 2007. Lifespan nutrition and changing socio-economic conditions in China. Asia Pac. J. Clin. Nutr. 16 (Suppl. 1): 374-382. (Pubitemid 46524630)
31. Fung, K. L., and M. M. Gottesman. 2009. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta. 1794: 860-871.
32. Roden, D. M., and A. L. George, Jr. 2002. The genetic basis of variability in drug responses. Nat. Rev. Drug Discov. 1: 37-44. (Pubitemid 37361402)
33. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459. (Pubitemid 39050440)
34. Mangravite, L. M., C. F. Thorn, and R. M. Krauss. 2006. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6: 360-374. (Pubitemid 44811531)
35. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379. (Pubitemid 40530265)
36. Hu, M., S. S. Lui, V. W. Mak, T. T. Chu, V. W. Lee, E. W. Poon, T. K. Tsui, G. T. Ko, L. Baum, L. S. Tam, et al. 2010. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics. 20: 634-637.
37. van der Baan, F. H., M. J. Knol, A. H. Maitland-van der Zee, J. J. Regieli, E. P. van Iperen, A. C. Egberts, O. H. Klungel, D. E. Grobbee, and J. W. Jukema. 2013. Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. Pharmacogenomics J. 13: 318-324.
38. Jakulj, L., H. Mohammed, T. H. van Dijk, T. Boer, S. Turner, A. K. Groen, M. N. Vissers, and E. S. Stroes. 2013. Plasma plant sterols serve as poor markers of cholesterol absorption in man. J. Lipid Res. 54: 1144-1150.
39. Mackay, D., and P. J. Jones. 2011. Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. Atherosclerosis. 218: 253-262.
40. Mitchell, J. C., G. M. Logan, B. G. Stone, and W. C. Duane. 1991. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J. Lipid Res. 32: 71-78.
41. Vanhanen, H., Y. A. Kesaniemi, and T. A. Miettinen. 1992. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism. 41: 588-595.
42. Smith, J. L., P. D. Roach, L. N. Wittenberg, M. Riottot, S. P. Pillay, P. J. Nestel, and L. K. Nathanson. 2000. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J. Gastroenterol. Hepatol. 15: 871-879.